Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 4,207 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 4,207 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $84,644.84. Following the completion of the sale, the insider now directly owns 85,236 shares in the company, valued at approximately $1,714,948.32. The trade was a 4.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.76, for a total value of $8,254.40.
• On Friday, January 3rd, Jula Inrig sold 2,066 shares of Travere Therapeutics stock. The stock was sold at an average price of $19.10, for a total value of $39,460.60.

Travere Therapeutics Stock Down 0.5 %

NASDAQ:TVTX traded down $0.11 on Friday, hitting $21.75. 2,442,302 shares of the company's stock were exchanged, compared to its average volume of 1,303,585. The firm has a 50-day moving average price of $18.86 and a 200-day moving average price of $15.64. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $22.25. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company has a market cap of $1.70 billion, a P/E ratio of -4.78 and a beta of 0.72.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Aigen Investment Management LP bought a new stake in Travere Therapeutics in the 3rd quarter valued at $170,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Travere Therapeutics during the 3rd quarter worth about $673,000. FMR LLC boosted its holdings in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company's stock worth $2,062,000 after buying an additional 31,772 shares during the period. Two Sigma Advisers LP raised its holdings in Travere Therapeutics by 30.2% in the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company's stock valued at $10,078,000 after acquiring an additional 167,100 shares during the period. Finally, Geode Capital Management LLC lifted its position in Travere Therapeutics by 3.9% during the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company's stock worth $24,222,000 after acquiring an additional 64,744 shares during the last quarter.

Wall Street Analyst Weigh In

TVTX has been the subject of a number of research analyst reports. HC Wainwright lifted their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, January 15th. Piper Sandler upped their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a "neutral" rating in a research report on Thursday, November 14th. Scotiabank boosted their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a "sector outperform" rating in a research report on Friday, November 1st. Wells Fargo & Company upgraded Travere Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $9.00 to $27.00 in a research report on Monday, October 21st. Finally, Barclays boosted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Travere Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $24.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.